Tracon pharmaceuticals, inc. (TCON)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14
Collaboration revenue

-

-

0

0

-

3,000

10,498

11,129

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

Collaboration revenue

-

-

-

-

-

-

-

-

-

-

-

-

2,865

-

4,227

4,592

7,982

7,904

7,549

7,502

4,374

3,598

0

0

0

Operating expenses:
Research and development

11,314

14,530

18,548

22,468

26,236

30,460

29,152

26,433

23,211

19,355

19,499

19,773

21,653

21,566

27,358

28,712

27,344

25,680

17,683

14,067

10,222

7,652

0

0

0

General and administrative

7,703

7,766

7,667

7,749

7,478

7,280

7,211

6,951

7,397

7,610

7,804

7,838

7,814

7,859

7,606

7,255

6,687

5,691

4,750

3,787

2,711

2,125

0

0

0

Total operating expenses

19,017

22,296

26,215

30,217

33,714

37,740

36,363

33,384

30,608

26,965

27,303

27,611

29,467

29,425

34,964

35,967

34,031

31,371

22,433

17,854

12,933

9,777

0

0

0

Loss from operations

-19,017

-22,296

-26,215

-30,217

-33,714

-34,740

-33,363

-22,886

-19,479

-18,210

-17,931

-24,922

-26,602

-25,976

-30,737

-31,375

-26,049

-23,467

-14,884

-10,352

-8,559

-6,179

0

0

0

Other expense:
Interest expense, net

-473

-386

-280

-172

-108

-231

-409

-620

-830

-886

-929

-993

-1,051

-1,119

-1,092

-1,029

0

-

0

0

-

-

-

-

-

Interest expense, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

0

0

0

Other expense, net

8

8

1

9

14

12

9

-2

-11

-7

3

17

24

87

89

85

68

-20

-42

-43

-25

37

0

0

0

Total other expense

-465

-378

-279

-163

-94

-219

-400

-622

-841

-893

-926

-976

-1,027

-1,032

-1,004

-942

-892

-943

-1,028

-1,032

-884

-630

0

0

0

Net loss

-19,482

-22,674

-26,494

-30,380

-33,808

-34,959

-33,763

-23,508

-20,320

-19,103

-18,857

-25,898

-27,629

-27,008

-31,741

-32,317

-26,941

-24,410

-15,912

-11,384

-9,443

-6,809

0

0

0

Accretion to redemption value of redeemable convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

31

0

0

0

-

-

-

-

Accretion to redemption value of redeemable convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Net loss attributable to common stockholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-24,441

-16,038

-11,580

-9,705

-7,106

0

0

0

Net loss per share, basic and diluted

-0.78

-4.68

-0.17

-0.21

-2.41

-11.88

-0.30

-0.33

-0.46

-10.60

0.07

-0.40

-0.44

-0.43

-0.48

-0.68

-0.54

-0.93

-0.53

-0.24

-0.50

-1.64

-1.23

-0.65

-0.88

Weighted-average shares outstanding, basic

-

-

-

-

-

-

-

-

-

-

16,828

-

-

-

12,227

-

-

-

-

-

-

-

-

-

-

Weighted-average shares outstanding, diluted

-

-

-

-

-

-

-

-

-

-

17,137

-

-

-

12,227

-

-

-

-

-

-

-

-

-

-

Weighted-average shares outstanding, basic and diluted

5,171

-50,718

29,937

29,929

2,989

-66,980

29,837

29,706

18,214

-

-

16,610

16,206

-

-

12,195

12,179

12,223

12,117

12,096

8,024

1,615

1,615

1,614

1,614